Abstract
Carcinomas of unknown primary site (CUP) are defined by the development of an epithelial metastatic disease (epidermoid carcinomas, well or poorly differentiated adenocarcinomas, poorly differentiated or undifferentiated carcinomas) in cases where the clinical, biological, and radiological examinations fail to identify the origin at the time of the therapeutic decision (Abbruzzese et al. 1994, 1995). In a general medical oncology service, metastatic carcinomas from an unknown primary site (CUP) constitute as many as 3-5% of referred patients with solid tumors (Seve 2008; Pavlidis et al. 2003). However, this incidence varies depending on the definition of CUP, the extent of the investigations that are performed, and the details of the patient population (Seve 2008). CUPs represent clinical problems that necessitate significant interactions between pathologists, oncologists, and primary physicians. The prognosis for these forms of cancer is regarded as very poor, with <10% of survival at 5 years (Abbruzzese et al. 1994).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, and Frost P (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12:1272-1280
Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, and Raber MN (1995) Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13:2094-2103
Alberini JL, Belhocine T, Hustinx R, Daenen F, and Rigo P (2003) Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome). Nucl Med Commun 24:1081-1086
Ambrosini V, Nanni C, Rubello D, Moretti A, Battista G, Castelluci P, Farsad M, Rampin L, Fiorentini G, Franchi F, Canini R, and Fanti S (2007) 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med 111:1146-1155
Bohuslavizki KH, Klutmann S, Kroger S, Sonnemann U, Buchert R, Werner JA, Mester J, and Clausen M (2000) FDG PET detection of unknown primary tumors. J Nucl Med 41:816-822
Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, and Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, and Fizazi K (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20:4679-4683
Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, and Fizazi K (2003) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study - trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 21:3479-3482
Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, and Carreras JL (2003) Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 44:1301-1314
Erasmus JJ, and Patz EF Jr (1999) Positron emission tomography imaging in the thorax. Clin Chest Med 20:715-724
Fencl P, Belohlavek O, Skopalova M, Jaruskova M, Kantorava I, and Simomova K (2007) Prognostic and diagnostic accuracy of FDG-PET/CT in 190 patients with carcinoma of unknown primary. Eur J Nucl Mol Imag [epub ahead of print]
Fogarty GB, Peters LJ, Stewart J, Scott C, Rischin D, and Hicks RJ (2003) The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor. Head Neck 25:138-145
Garin E, Prigent-Lejeune F, Lesimple T, Barge ML, Rousseau C, Devillers A, Bouriel C, Mesbah H, Bernard AM, Bridji B, and Resche I (2007) Impact of PET-FDG in the diagnosis and therapeutic care of patients presenting with metastases of unknown primary. Cancer Invest 25:232-239
Greco FA, Gray J, Burris HA III, Erland JB, Morrissey LH, and Hainsworth JD (2001) Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J 7:203-212
Gupta NC, Nicholson P, and Bloomfield SM (1999) FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors. Ann Surg 230:202-206
Gutzeit A, Antoch G, Kuhl H, Egelhof T, Fischer M, Hauth E, Goehde S, Bockisch A, Debatin J, and Freudenberg L (2005) Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology 234:227-234
Hess KR, Abbruzzese MC, Lenzi R, Raber MN, and Abbruzzese JL (1999) Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403-3410
Hiibner G, Wildfang I, and Schmoll HJ, CUP (1999) In: Schmoll HJ (ed) Kompendium Internistische Onkologie Band 2. Berlin/Heidelberg/New York: Springer, pp 2137-2182
Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Schraffordt Koops H, Roodenburg JLN, Vaalburg W, and Vermey A (1998) Dtection of unknown occult primary tumors using positron emission tomography. Cancer 82:1160-1166
Kolesnikov-Gauthier H, Levy E, Merlet P, Kirova J, Syrota A, Carpentier P, Meignan M, and Piedbois P (2005) FDG PET in patients with cancer of an unknown primary. Nucl Med Commun 26:1059-1066
Lassen U, Daugaard G, Eigtved A, Damgaard K, and Friberg L (1999) 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 35:1076-1082
Lonneux M, and Reffad A (2000) Metastases from unknown primary tumor. PET-FDG as initial diagnostic procedure? Clin Positron Imag 3: 137-141
Mantaka P, Baum RP, Hertel A, Adams S, Niessen A, Sengupta S, and Hor G (2003) PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (FDG) in patients with cancer of unknown primary (CUP): influence on patients' diagnostic and therapeutic management. Cancer Biother Radiopharm 18:47-58
Nanni C, Rubello D, Castellucci P, Farsad M, Franchi R, Toso S, Barile C, Rampin L, Nibale O, and Fanti S (2005) Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imag 32:589-592
Nieder C, Gregoire V, and Ang KK (2001) Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 50:727-733
Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM (1977) Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4:53-58
Pavlidis N, Briasoulis E, Hainsworth J, and Greco FA (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990-2005
Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, and Bisi G (2006) Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site. Q J Nucl Med Mol Imag 50:15-22
Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, and Somerfield MR, A Society of Clinical Oncology (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update. J Clin Oncol 22:330-353
Rades D, Kuhnel G, Wildfang I, Borner AR, Schmoll HJ, and Knapp W (2001) Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann Oncol 12:1605-1609
Scott CL, Kudaba I, Stewart JM, Hicks RJ, and Rischin D (2005) The utility of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in the investigation of patients with disseminated carcinoma of unknown primary origin. Mol Imag Biol 7:236-243
Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, and Mackey JR (2006) The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Cancer 106:2058-2066
Seve P (2008) Clinical presentations. In: Wick MR (ed) Metastatic carcinoma of unknown primary. New York: Demos, pp 1-26
Seve P, Billotey C, Broussolle C, Dumontet C, and Mackey JR (2007) The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109:292-299
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Sève, P., Mackey, J.R. (2010). Disseminated Carcinoma of Unknown Primary Site: Detection with F-Fluorodeoxyglucose-Positron Emission Tomography. In: Hayat, M. (eds) Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 7. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-3186-0_5
Download citation
DOI: https://doi.org/10.1007/978-90-481-3186-0_5
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-3185-3
Online ISBN: 978-90-481-3186-0
eBook Packages: MedicineMedicine (R0)